---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-26-000028"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:49:17.355600+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kiora Pharmaceuticals CDO Eric Daniels to resign April 17; successor search initiated

## Summary
- Eric J. Daniels resigns as Chief Development Officer effective April 17, 2026, to pursue other opportunities.
- Resignation not due to any disagreement with company's operations, policies, or practices.
- Company has initiated a search for Daniels' successor; CEO thanked Daniels for his contributions.
- Kiora continues enrollment in KIO-301 (ABACUS-2) and KIO-104 (KLARITY) Phase 2 trials.
- Safety reviews cleared for KIO-301 50µg and 100µg dose cohorts; KIO-104 enrollment ongoing.

## SEC filing metadata
- accession: 0001372514-26-000028
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000028/0001372514-26-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000028/kprx-20260401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-26-000028
- JSON: https://secwatch.observer/filing/0001372514-26-000028.json
- Plain text: https://secwatch.observer/filing/0001372514-26-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.